{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:33:33Z","timestamp":1792704813125,"version":"4.5.0"},"reference-count":74,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL128168"],"award-info":[{"award-number":["R01HL128168"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R21AG072205"],"award-info":[{"award-number":["R21AG072205"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F32CA275298"],"award-info":[{"award-number":["F32CA275298"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K00CA234940"],"award-info":[{"award-number":["K00CA234940"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA214913"],"award-info":[{"award-number":["R01CA214913"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA247441"],"award-info":[{"award-number":["R01CA247441"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA284372"],"award-info":[{"award-number":["R01CA284372"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA284603"],"award-info":[{"award-number":["R01CA284603"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA261842"],"award-info":[{"award-number":["U01CA261842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001513","name":"Breast Cancer Alliance","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016872","name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100016872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapies have revolutionized cancer care in recent decades, but approved therapies often fail and currently only target specific steps in the generation of anti-cancer immune responses. Notably, the majority of approved immunotherapies do not target antigen processing and presentation, which are key steps in the development of immune responses and harbor potential as targets to improve immunotherapy. Here, we hypothesize that tumor-mediated alterations in cytokine concentrations alter antigen presentation, which can be normalized by locoregional cytokine delivery or targeted immunological adjuvant delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used mouse models of breast cancer, with analysis by flow cytometry, immunofluorescence, confocal imaging, and single-cell RNA sequencing to address the impacts of tumors on locoregional antigen presentation, along with mechanisms to remedy these impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we demonstrate that breast tumors induce locoregional impairments in dendritic cell antigen presentation that limits anti-cancer antigen-specific T cell responses. Antigen processing was not impaired in dendritic cells within the tumor-draining lymph node. A reduction of the cytokine IL-1\u03b2 in tumor-draining lymph nodes was responsible for impairments in antigen presentation by dendritic cells. As such, we tested the ability of dendritic cells in lymph nodes at various distances from the primary tumor to be activated utilizing an antigen-agnostic immunological adjuvant delivery strategy. We observed improved antitumor T cell responses when immunological adjuvant was delivered to cancer antigen-positive lymph nodes distant from the tumor, suggesting that these lymph nodes can be targeted to improve anti-cancer immune responses. When combined with immune checkpoint blockade, delivery of immunological adjuvant to distant lymph nodes led to long-term survival and protection from recurrence. Antigen presentation by dendritic cells and T cell responses could also be recovered by exogenous delivery of IL-1\u03b2 via intratumoral injection, with improved survival when combined with immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates that tumor-induced impairments in antigen presentation in tumor-draining lymph nodes can be overcome by the appropriate introduction of immunological adjuvant to tumor-distant lymph nodes or by restoring IL-1\u03b2 to the tumor-draining lymph node. These strategies can induce high-quality, durable immune responses and have clinical implications for expanding the efficacy of immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013364","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T19:00:21Z","timestamp":1767121221000},"page":"e013364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2223-1849","authenticated-orcid":false,"given":"Meghan J.","family":"O\u2019Melia","sequence":"first","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Menzel","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-5179","authenticated-orcid":false,"given":"Pin-Ji","family":"Lei","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengbo","family":"Zhou","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjian","family":"Zhang","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neian","family":"Contreras-Alvarado","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"School of Medicine, University of Puerto Rico, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna J","family":"Rajotte","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingshan","family":"Liu","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R","family":"Nikmaneshi","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W","family":"Baish","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Bucknell University, Lewisburg, West Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessalyn M","family":"Ubellacker","sequence":"additional","affiliation":[{"name":"Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P","family":"Padera","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance L","family":"Munn","sequence":"additional","affiliation":[{"name":"E. L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2025123022300876000_13.12.e013364.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2025123022300876000_13.12.e013364.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"2025123022300876000_13.12.e013364.3","doi-asserted-by":"crossref","unstructured":"Farkona S , Diamandis EP , Blasutig IM . Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016;14. doi:10.1186\/s12916-016-0623-5","DOI":"10.1186\/s12916-016-0623-5"},{"key":"2025123022300876000_13.12.e013364.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"2025123022300876000_13.12.e013364.5","doi-asserted-by":"crossref","unstructured":"Gajewski TF . Cancer immunotherapy. In: Mol Oncol. John Wiley and Sons Ltd, 2012: 242\u201350. Available: https:\/\/doi.org\/10.1016\/j.molonc.2012.01.002","DOI":"10.1016\/j.molonc.2012.01.002"},{"key":"2025123022300876000_13.12.e013364.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2025123022300876000_13.12.e013364.7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-70197-4_10"},{"key":"2025123022300876000_13.12.e013364.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"key":"2025123022300876000_13.12.e013364.9","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9101060","article-title":"mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients","volume":"9","author":"Bidram","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025123022300876000_13.12.e013364.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126388","article-title":"The Treatment of Advanced Melanoma: Therapeutic Update","volume":"23","author":"Villani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025123022300876000_13.12.e013364.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0"},{"key":"2025123022300876000_13.12.e013364.12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","article-title":"Therapeutic vaccines for breast cancer: Has the time finally come?","volume":"160","author":"Corti","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025123022300876000_13.12.e013364.13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031010"},{"key":"2025123022300876000_13.12.e013364.14","doi-asserted-by":"crossref","unstructured":"Zhu S-Y , Yu K-D . Breast Cancer Vaccines: Disappointing or Promising? Front Immunol 2022;13. doi:10.3389\/fimmu.2022.828386","DOI":"10.3389\/fimmu.2022.828386"},{"key":"2025123022300876000_13.12.e013364.15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of Cancer Resistance to Immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"key":"2025123022300876000_13.12.e013364.16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-070621-030155"},{"key":"2025123022300876000_13.12.e013364.17","doi-asserted-by":"crossref","first-page":"100718","DOI":"10.1016\/j.drup.2020.100718","article-title":"Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies","volume":"53","author":"P\u00e9rez-Ruiz","year":"2020","journal-title":"Drug Resist Updat"},{"key":"2025123022300876000_13.12.e013364.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to Checkpoint Inhibition in Cancer Immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl Oncol"},{"key":"2025123022300876000_13.12.e013364.19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040935","article-title":"Future Challenges in Cancer Resistance to Immunotherapy","volume":"12","author":"van Elsas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025123022300876000_13.12.e013364.20","doi-asserted-by":"crossref","unstructured":"Zheng Y , Li S , Tang H , et al . Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1153990","DOI":"10.3389\/fimmu.2023.1153990"},{"key":"2025123022300876000_13.12.e013364.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2025123022300876000_13.12.e013364.22","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/cam4.3295","article-title":"EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty","volume":"9","author":"Le Naour","year":"2020","journal-title":"Cancer Med"},{"key":"2025123022300876000_13.12.e013364.23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122211","article-title":"Dendritic Cells in Shaping Anti-Tumor T Cell Response","volume":"16","author":"Mazzoccoli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025123022300876000_13.12.e013364.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081976","article-title":"The Role of Type-2 Conventional Dendritic Cells in the Regulation of Tumor Immunity","volume":"14","author":"Saito","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025123022300876000_13.12.e013364.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6"},{"key":"2025123022300876000_13.12.e013364.26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221847","article-title":"Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes","volume":"220","author":"Lei","year":"2023","journal-title":"J Exp Med"},{"key":"2025123022300876000_13.12.e013364.27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature New Biol"},{"key":"2025123022300876000_13.12.e013364.28","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E04-04-0342"},{"key":"2025123022300876000_13.12.e013364.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309828"},{"key":"2025123022300876000_13.12.e013364.30","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201411093"},{"key":"2025123022300876000_13.12.e013364.31","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900464","article-title":"The role of MHC class I recycling and Arf6 in cross-presentation by murine dendritic cells","volume":"2","author":"Montealegre","year":"2019","journal-title":"Life Sci Alliance"},{"key":"2025123022300876000_13.12.e013364.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2012.04.010"},{"key":"2025123022300876000_13.12.e013364.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02792-5"},{"key":"2025123022300876000_13.12.e013364.34","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955683","article-title":"The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma","volume":"4","author":"Zelba","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025123022300876000_13.12.e013364.35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e20504","article-title":"Peripheral pre-existing cancer-antigen specific T-cell immunity as predictive biomarker for immunotherapy in NSCLC patients","volume":"41","author":"Xagara","year":"2023","journal-title":"JCO"},{"key":"2025123022300876000_13.12.e013364.36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177082","article-title":"T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma","volume":"134","author":"Hansen","year":"2024","journal-title":"J Clin Invest"},{"key":"2025123022300876000_13.12.e013364.37","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.18632\/oncotarget.27666","article-title":"Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer","volume":"11","author":"Tsuji","year":"2020","journal-title":"Oncotarget"},{"key":"2025123022300876000_13.12.e013364.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33720-z","article-title":"Evolution and modulation of antigen-specific T cell responses in melanoma patients","volume":"13","author":"Huuhtanen","year":"2022","journal-title":"Nat Commun"},{"key":"2025123022300876000_13.12.e013364.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01331-8"},{"key":"2025123022300876000_13.12.e013364.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0828"},{"key":"2025123022300876000_13.12.e013364.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-018-1434-0","article-title":"Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome","volume":"19","author":"Zapata","year":"2018","journal-title":"Genome Biol"},{"key":"2025123022300876000_13.12.e013364.42","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0599"},{"key":"2025123022300876000_13.12.e013364.43","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10071120","article-title":"Advances in Infectious Disease Vaccine Adjuvants","volume":"10","author":"Fan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2025123022300876000_13.12.e013364.44","unstructured":"Matsiko A . Alum adjuvant discovery and potency. Nat Med 2020."},{"key":"2025123022300876000_13.12.e013364.45","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.038943-0"},{"key":"2025123022300876000_13.12.e013364.46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071087"},{"key":"2025123022300876000_13.12.e013364.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002806117"},{"key":"2025123022300876000_13.12.e013364.48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.humimm.2018.06.002","article-title":"IL-1\u03b2 induces expression of costimulatory molecules and cytokines but not immune feedback regulators in dendritic cells","volume":"79","author":"Michelini","year":"2018","journal-title":"Hum Immunol"},{"key":"2025123022300876000_13.12.e013364.49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613170"},{"key":"2025123022300876000_13.12.e013364.50","doi-asserted-by":"crossref","first-page":"872155","DOI":"10.3389\/fimmu.2022.872155","article-title":"What Is IL-1 for? The Functions of Interleukin-1 Across Evolution","volume":"13","author":"Boraschi","year":"2022","journal-title":"Front Immunol"},{"key":"2025123022300876000_13.12.e013364.51","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.25"},{"key":"2025123022300876000_13.12.e013364.52","doi-asserted-by":"crossref","unstructured":"R\u00e9b\u00e9 C , Ghiringhelli F . n.d. Interleukin-1\u03b2 and Cancer. Cancers (Basel) 12:1791. doi:10.3390\/cancers12071791","DOI":"10.3390\/cancers12071791"},{"key":"2025123022300876000_13.12.e013364.53","doi-asserted-by":"crossref","first-page":"621931","DOI":"10.3389\/fimmu.2020.621931","article-title":"Interleukin-1 as Innate Mediator of T Cell Immunity","volume":"11","author":"Van Den Eeckhout","year":"2020","journal-title":"Front Immunol"},{"key":"2025123022300876000_13.12.e013364.54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-011404","article-title":"IL-1\u03b2 blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","volume":"13","author":"Talele","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2025123022300876000_13.12.e013364.55","first-page":"61","article-title":"Mechanism of acute toxicity of IL-1 beta in mice","volume":"2","author":"Boraschi","year":"1991","journal-title":"Eur Cytokine Netw"},{"key":"2025123022300876000_13.12.e013364.56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0019-T"},{"key":"2025123022300876000_13.12.e013364.57","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.breast.2023.01.009","article-title":"Axillary lymph node dissection: Dead or still alive?","volume":"69","author":"Beck","year":"2023","journal-title":"The Breast"},{"key":"2025123022300876000_13.12.e013364.58","first-page":"176","article-title":"Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer","volume":"8","author":"Gherghe","year":"2015","journal-title":"J Med Life"},{"key":"2025123022300876000_13.12.e013364.59","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/SLA.0000000000005671","article-title":"Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis","volume":"277","author":"Che Bakri","year":"2023","journal-title":"Ann Surg"},{"key":"2025123022300876000_13.12.e013364.60","doi-asserted-by":"crossref","unstructured":"Zhou H , Baish JW , MJ O , et al . n.d. Cancer immunotherapy responses persist after lymph node 1 resection 2. bioRxiv. doi:10.1101\/2023.09.19.558262","DOI":"10.1101\/2023.09.19.558262"},{"key":"2025123022300876000_13.12.e013364.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2006.01.022"},{"key":"2025123022300876000_13.12.e013364.62","doi-asserted-by":"publisher","DOI":"10.1080\/01926230600867727"},{"key":"2025123022300876000_13.12.e013364.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2007.11.012"},{"key":"2025123022300876000_13.12.e013364.64","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202304076","article-title":"Transport Barriers Influence the Activation of Anti-Tumor Immunity: A Systems Biology Analysis","volume":"10","author":"Nikmaneshi","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2025123022300876000_13.12.e013364.65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coche.2014.11.003","article-title":"Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery","volume":"7","author":"Thomas","year":"2015","journal-title":"Curr Opin Chem Eng"},{"key":"2025123022300876000_13.12.e013364.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.04.011"},{"key":"2025123022300876000_13.12.e013364.67","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature08604","article-title":"Materials engineering for immunomodulation","volume":"462","author":"Hubbell","year":"2009","journal-title":"Nature New Biol"},{"key":"2025123022300876000_13.12.e013364.68","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.1016\/j.biomaterials.2011.08.079","article-title":"PEG-b-PPS-b-PEI micelles and PEG-b-PPS\/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: Tumor immunotoxicity in B16F10 melanoma","volume":"32","author":"Velluto","year":"2011","journal-title":"Biomaterials"},{"key":"2025123022300876000_13.12.e013364.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.10.003"},{"key":"2025123022300876000_13.12.e013364.70","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd7134","article-title":"Quality of CD8+ T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context","volume":"6","author":"O\u2019Melia","year":"2020","journal-title":"Sci Adv"},{"key":"2025123022300876000_13.12.e013364.71","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108084","article-title":"Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening","volume":"34","author":"O\u2019Melia","year":"2022","journal-title":"Adv Mater"},{"key":"2025123022300876000_13.12.e013364.72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41565-020-0679-4","article-title":"Programmable multistage drug delivery to lymph nodes","volume":"15","author":"Schudel","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"2025123022300876000_13.12.e013364.73","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ajpath.2024.02.013","article-title":"Isolation and Characterization of a Novel Mammary Adenocarcinoma, MCa-P1362, with Hormone Receptor Expression, Human Epidermal Growth Factor Receptor 2 Positivity, and Enrichment in Cancer and Mesenchymal Stem Cells","volume":"194","author":"Jana","year":"2024","journal-title":"Am J Pathol"},{"key":"2025123022300876000_13.12.e013364.74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:30:19Z","timestamp":1767162619000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":74,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,30]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/jitc-2025-013364"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013364","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}